3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Uveal Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Eye Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
15
Nivolumab
10
avelumab
9
atezolizumab
8
Gemcitabine
8
Cisplatin
8
Magnetic Resonance Spectroscopy
6
durvalumab
5
Specimen Handling
5
Docetaxel
5
Carboplatin
5
Paclitaxel
4
Ipilimumab
4
tislelizumab
3
sacituzumab govitecan
3
enfortumab vedotin
3
Taxes
3
Pemetrexed
3
Mitomycin
3
eribulin
2
erdafitinib
2
cabozantinib
2
Doxorubicin
2
CTLA-4 Antigen
2
ALT-803
2
zimberelimab
1
veliparib
1
urelumab
1
tazemetostat
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Transitional Cell
×
belinostat
×
Clear all
NCT05154994
2026-05-07
RESOLVE
University of Utah
Phase 1
Active not recruiting
9 enrolled